RxDoctor Payments Data

Joann Pinkerton, MD

Obstetrics & Gynecology · Charlottesville, VANPI 1437283801

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,838 of the $34,880 with a category attached, or 71.2%. 5 manufacturers reported payments, led by Bayer at 52.3% of the total. Among obstetrics & gynecology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,880in general payments, 2019–2025

Across 34 payments — averaging $1025.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$18K
  • Merck$8K
  • Pfizer$7K
  • Astellas Pharma Global Development$938
  • Astellas Pharma US Inc$267

What the payments were for

  • Consulting fees$24,83871%
  • Speaking & faculty fees$6,00017%
  • Travel & lodging$3,63010%
  • Food & beverage$4121%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer12$18,236
Merck15$8,300
Pfizer4$7,139
Astellas Pharma Global Development1$938
Astellas Pharma US Inc2$267

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,880 in reported general payments places this provider in the 95th percentile of 992 obstetrics & gynecology providers in Virginia.

See all obstetrics & gynecology providers in Virginia

Medicare billing

Part B allowed, 2024
$152,314
Medicare patients
1,379
Services billed
1,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol989$108,816
PremarinEstrogens, Conjugated97$41,305
MyrbetriqMirabegron30$20,743
YuvafemEstradiol92$17,355
MenostarEstradiol46$14,624
Estradiol (Once Weekly)Estradiol118$12,948
Estradiol (Twice Weekly)Estradiol109$10,145
EstringEstradiol16$8,540
ProgesteroneProgesterone, Micronized247$6,144
IntrarosaPrasterone (Dhea)11$5,445
Clobetasol Propionate132$4,465
DottiEstradiol29$3,107
Raloxifene Hcl70$3,074
Fesoterodine Fumarate ErFesoterodine Fumarate35$3,048
ValacyclovirValacyclovir Hcl60$2,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Estring$7,139$49,844113 claims
Astellas Pharma US IncMyrbetriq$267$20,74330 claims
BayerMenostar$18,236$14,62446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 992 obstetrics & gynecology providers in Virginia.

Other obstetrics & gynecology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →